PortfoliosLab logoPortfoliosLab logo
OGN vs. MRK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

OGN vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Organon & Co. (OGN) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, OGN achieves a 87.63% return, which is significantly higher than MRK's 9.78% return.


OGN

1D
0.15%
1M
1.21%
YTD
87.63%
6M
85.05%
1Y
43.20%
3Y*
-8.35%
5Y*
-13.60%
10Y*

MRK

1D
-0.82%
1M
1.41%
YTD
9.78%
6M
13.95%
1Y
54.09%
3Y*
3.77%
5Y*
12.62%
10Y*
11.18%
*Multi-year figures are annualized to reflect compound growth (CAGR)

OGN vs. MRK - Yearly Performance Comparison


2026 (YTD)20252024202320222021
OGN
Organon & Co.
87.63%-50.71%9.92%-45.12%-4.86%-12.15%
MRK
Merck & Co., Inc.
9.78%9.79%-6.26%1.01%49.42%8.75%

Correlation

The correlation between OGN and MRK is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Jun 3, 2021

0.26

Fundamentals

Market Cap

OGN:

$3.52B

MRK:

$283.54B

EPS

OGN:

$0.94

MRK:

$3.58

PE Ratio

OGN:

14.22

MRK:

32.00

PS Ratio

OGN:

0.57

MRK:

4.36

PB Ratio

OGN:

3.90K

MRK:

6.18

Total Revenue (TTM)

OGN:

$6.16B

MRK:

$65.59B

Gross Profit (TTM)

OGN:

$3.27B

MRK:

$49.79B

EBITDA (TTM)

OGN:

$1.33B

MRK:

$22.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

OGN vs. MRK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OGN
OGN Risk / Return Rank: 6262
Overall Rank
OGN Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
OGN Sortino Ratio Rank: 6565
Sortino Ratio Rank
OGN Omega Ratio Rank: 6767
Omega Ratio Rank
OGN Calmar Ratio Rank: 5959
Calmar Ratio Rank
OGN Martin Ratio Rank: 5858
Martin Ratio Rank

MRK
MRK Risk / Return Rank: 8787
Overall Rank
MRK Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
MRK Sortino Ratio Rank: 8787
Sortino Ratio Rank
MRK Omega Ratio Rank: 8484
Omega Ratio Rank
MRK Calmar Ratio Rank: 9090
Calmar Ratio Rank
MRK Martin Ratio Rank: 8989
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OGN vs. MRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


OGNMRKDifference
Sharpe ratioReturn per unit of total volatility

-1.40

Sortino ratioReturn per unit of downside risk

-1.41

Omega ratioGain probability vs. loss probability

1.21

1.35

-0.14

Calmar ratioReturn relative to maximum drawdown

0.91

4.78

-3.88

Martin ratioReturn relative to average drawdown

1.82

12.00

-10.18

OGN vs. MRK - Sharpe Ratio Comparison

The current OGN Sharpe Ratio is 0.62, which is lower than the MRK Sharpe Ratio of 2.02. The chart below compares the historical Sharpe Ratios of OGN and MRK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


OGNMRKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.62

2.02

-1.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

0.54

-0.82

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.49

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.29

0.48

-0.77

Drawdowns

OGN vs. MRK - Drawdown Comparison

The maximum OGN drawdown since its inception was -82.69%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for OGN and MRK.


Loading charts...

Drawdown Indicators


OGNMRKDifference

Max Drawdown

Largest peak-to-trough decline

-82.69%

-68.61%

-14.08%

Max Drawdown (1Y)

Largest decline over 1 year

-47.96%

-11.37%

-36.59%

Max Drawdown (3Y)

Largest decline over 3 years

-74.10%

-43.44%

-30.66%

Max Drawdown (5Y)

Largest decline over 5 years

-82.69%

-43.44%

-39.25%

Max Drawdown (10Y)

Largest decline over 10 years

-43.44%

Current Drawdown

Current decline from peak

-59.26%

-8.50%

-50.76%

Average Drawdown

Average peak-to-trough decline

-43.15%

-18.84%

-24.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.81%

4.52%

+19.29%

Volatility

OGN vs. MRK - Volatility Comparison

The current volatility for Organon & Co. (OGN) is 1.33%, while Merck & Co., Inc. (MRK) has a volatility of 8.21%. This indicates that OGN experiences smaller price fluctuations and is considered to be less risky than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


OGNMRKDifference

Volatility (1M)

Calculated over the trailing 1-month period

1.33%

8.21%

-6.88%

Volatility (6M)

Calculated over the trailing 6-month period

52.85%

17.62%

+35.23%

Volatility (1Y)

Calculated over the trailing 1-year period

69.68%

26.92%

+42.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.81%

23.62%

+25.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.84%

22.91%

+25.93%

Dividends

OGN vs. MRK - Dividend Comparison

OGN's dividend yield for the trailing twelve months is around 0.60%, less than MRK's 2.89% yield.


PositionTTM20252024202320222021202020192018201720162015
MRK
Merck & Co., Inc.
2.89%3.12%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%
OGN
Organon & Co.
0.60%4.74%7.51%7.77%4.01%1.84%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

OGN vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between Organon & Co. and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
1.46B
16.29B
(OGN) Total Revenue
(MRK) Total Revenue
Values in USD except per share items

OGN vs. MRK - Profitability Comparison

The chart below illustrates the profitability comparison between Organon & Co. and Merck & Co., Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%55.0%60.0%65.0%70.0%75.0%80.0%85.0%20222023202420252026
53.6%
81.9%
Portfolio components
OGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported a gross profit of 783.00M and revenue of 1.46B. Therefore, the gross margin over that period was 53.6%.

MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a gross profit of 13.34B and revenue of 16.29B. Therefore, the gross margin over that period was 81.9%.

OGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported an operating income of 266.00M and revenue of 1.46B, resulting in an operating margin of 18.2%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported an operating income of -1.88B and revenue of 16.29B, resulting in an operating margin of -11.6%.

OGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported a net income of 146.00M and revenue of 1.46B, resulting in a net margin of 10.0%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a net income of -4.24B and revenue of 16.29B, resulting in a net margin of -26.0%.


Frequently Asked Questions


OGN and MRK have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MRK has higher volatility (8.21%) compared to OGN (1.33%). In terms of maximum drawdown, OGN dropped -82.69% vs MRK's -68.61%.

MRK currently has the higher Sharpe Ratio (2.02 vs 0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for OGN and MRK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer